Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Current Taxes (2021 - 2025)

Indivior Pharmaceuticals has reported Current Taxes over the past 5 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Current Taxes at $2.0 million for Q4 2025, down 71.43% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (down 71.43% YoY), and the annual figure for FY2025 was $2.0 million, down 71.43%.
  • Current Taxes for Q4 2025 was $2.0 million at Indivior Pharmaceuticals, down from $4.0 million in the prior quarter.
  • Over the last five years, Current Taxes for INDV hit a ceiling of $17.0 million in Q2 2025 and a floor of $2.0 million in Q4 2025.
  • Median Current Taxes over the past 5 years was $7.5 million (2021), compared with a mean of $8.2 million.
  • Biggest five-year swings in Current Taxes: rose 28.57% in 2022 and later tumbled 71.43% in 2025.
  • Indivior Pharmaceuticals' Current Taxes stood at $7.0 million in 2021, then rose by 28.57% to $9.0 million in 2022, then fell by 11.11% to $8.0 million in 2023, then fell by 12.5% to $7.0 million in 2024, then tumbled by 71.43% to $2.0 million in 2025.
  • The last three reported values for Current Taxes were $2.0 million (Q4 2025), $4.0 million (Q3 2025), and $17.0 million (Q2 2025) per Business Quant data.